Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
AstraZeneca
Colorcon
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,303,146

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,303,146 protect, and when does it expire?

Patent 6,303,146 protects GLUCOVANCE and is included in one NDA.

Protection for GLUCOVANCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-six countries.

Summary for Patent: 6,303,146
Title: Solid oral dosage form comprising a combination of metformin and glibenclamide
Abstract:The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.
Inventor(s): Bonhomme; Yves (Charbonnieres les Bains, FR), Nicholson; Geoffrey (Aylesbury, GB), Cave; Gillian (Ellesmere Port, GB), Nicholson; Sarah J. (Helsby, GB)
Assignee: LIPHA (Lyons, FR)
Application Number:09/353,141
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Process; Formulation; Use;

Drugs Protected by US Patent 6,303,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-001 Jul 31, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-002 Jul 31, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178-003 Jul 31, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,303,146

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98401781Jul 15, 1998

International Family Members for US Patent 6,303,146

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1450   Start Trial
Argentina 013052   Start Trial
Argentina 065970   Start Trial
Austria 250418   Start Trial
Australia 2003261560   Start Trial
Australia 5417999   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKinsey
Merck
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.